PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism.

ABSTRACT:

Background

Malignant melanoma is the most lethal form of skin cancer which shows BRAF mutation in 50% of patients. In this context, the identification of BRAF^V600E mutation led to the development of specific inhibitors like PLX4032. Nevertheless, although its initial success, its clinical efficacy is reduced after six-months of therapy leading to cancer relapse due to the onset of drug resistance. Therefore, investigating the mechanisms underlying PLX4032 resistance is fundamental to improve therapy efficacy. In this context, several models of PLX4032 resistance have been developed, but the discrepancy between in vitro and in vivo results often limits their clinical translation.

Methods

The herein reported model has been realized by treating with PLX

SUBMITTER: Garbarino O 

PROVIDER: S-EPMC10391174 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature